Head & Neck Institute Outcomes
Head and Neck Surgery and Oncology
Locoregional and Distant Recurrence for HPV-Associated Oropharyngeal Cancer Using AJCC 8 Staging
2002-2018
The objective of this study is to evaluate locoregional and distant failure for human papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) using American Joint Committee on Cancer eighth edition (AJCC 8) staging.
Locoregional Control for HPV+ Oropharyngeal Squamous Cell Carcinoma After Platinum-base Chemoradiation by RPA Class (N = 457)
2002-2018
| Years Post Chemoradiation | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| T1-3 < 19 Pack-Years (N = 247) | 212 | 178 | 143 | 121 | 105 |
| T1-3 ≥ 19 Pack-Years (N = 130) | 106 | 90 | 77 | 64 | 49 |
| T4 (N = 80) | 57 | 49 | 47 | 39 | 34 |
Locoregional Control for HPV+ Oropharyngeal Squamous Cell Carcinoma After Platinum-base Chemoradiation by AJCC 8 Stage (N = 457)
2002-2018
| Years Post Chemoradiation | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| AJCC 8 Stage I (N = 219) | 181 | 154 | 128 | 113 | 92 |
| AJCC 8 Stage II (N = 128) | 112 | 91 | 70 | 54 | 45 |
| AJCC 8 Stage III (N = 110) | 82 | 72 | 69 | 57 | 51 |
Distant Control for HPV+ Oropharyngeal Squamous Cell Carcinoma After Platinum-based Chemoradiation by RPA Stage (N = 457)
2002-2018
| Years Post Chemoradiation | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Former/Never Smoker (N = 362) | 314 | 259 | 218 | 184 | 155 |
| Current Smoker (N = 95) | 64 | 54 | 41 | 35 | 30 |
Distant Control for HPV+ Oropharyngeal Squamous Cell Carcinoma After Platinum-based Chemoradiation by AJCC 8 Stage (N = 457)
2002-2018
| Years Post Chemoradiation | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| AJCC Stage I (N = 219) | 180 | 148 | 124 | 110 | 89 |
| AJCC Stage II (N = 128) | 112 | 91 | 67 | 52 | 44 |
| AJCC Stage III (N = 110) | 86 | 74 | 68 | 57 | 52 |
In the largest evaluation of HPV+ OPSCC after platinum-based chemoradiation using AJCC 8, risk for locoregional recurrence was stratified by smoking, T category, N category, and overall stage. Risk of distant recurrence was only stratified by smoking status and not related to stage. This has implications for surveillance and clinical trial design.
